Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 5/2000

01-05-2000 | Leading Article

Prospects for Vaccination in Prostate Cancer

Authors: Matthew J. A. Perry, David Hrouda, Angus G. Dalgleish

Published in: Drugs & Aging | Issue 5/2000

Login to get access

Abstract

Prostate cancer continues to be a major cause of morbidity and mortality. Surgical and medical management of the disease has improved but there is little effect upon overall survival. Novel therapies such as immunotherapy offer the potential of treating the disease by stimulating the immune system to mount a response to the cancer systemically. This review highlights the pitfalls and progress in the understanding of the role of the immune system in malignancy and also explains the theory behind prostate cancer vaccine trials.
Literature
1.
Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop 1991; 262: 3–11PubMed
2.
Bumet FM. Immunological surveillance. Oxford: Pergamon Press, 1970
3.
Vesalainen S, Lipponen R, Talja M, et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis inprostatic adenocarcinoma. Eur J Cancer 1994; 30A(12): 1797–803PubMedCrossRef
4.
Bostwick DG, Conica FA, Dundore P, et al. Intraepithelial and stromal lymphocytes in the human prostate [abstract]. J Urol 1998; 159(5 Suppl.): 126
5.
Merrin C, Han T, Klein E, et al. Immunotherapy of prostatic cancer with Bacillus Calmette-Guerin and purified protein derivative: preliminary results. Urology 1973; 2(6): 651–4PubMedCrossRef
6.
Guinan R, Toronchi E, Shaw M, et al. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 1982; 20(4): 401–3PubMedCrossRef
7.
Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996; 3(10): 845–52PubMed
8.
van der Bruggen P, Traversari C, Chomez R, et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–7PubMedCrossRef
9.
Coulle PG. Human tumor antigens recognised by cytolytic T lymphocytes. In: Dalgleish AG, Browning M, editors. Tumor immunology. Cambridge, England: Cambridge Press, 1996: 95–125
10.
Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54(7): 1807–11PubMed
11.
Tjoa B, Boynton A, Kenny G, et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996; 28(1): 65–9PubMedCrossRef
12.
Corman JM, Sercarz ES, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 1998; 114(2): 166–72PubMedCrossRef
13.
Correale RP, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89(4): 293–300PubMedCrossRef
14.
Brenner PC, Rettig WJ, Sanz-Moncasi MP, et al. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol 1995; 153(5): 1575–9PubMedCrossRef
15.
Zliang S, Zliang HS, Reuter VE, et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4(2): 295–302
16.
Zinkernagel RM, Doherty PC. MHC restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity, function and responsiveness. Adv Immunol 1979; 26: 51–177CrossRef
17.
Blades RA, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46(5): 681–6PubMedCrossRef
18.
Restifo NR, Kawakami Y, Marincola F, et al. Molecular mechanisms used by tumors to escape recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 1993; 142: 182–90CrossRef
19.
Restifo NP, Wang M. Antigen processing and presentation. In: Dalgleish AG, Browning M, editors. Tumor immunology. Cambridge, England: Cambridge Press, 1996: 39–69
20.
Rosenberg SA, Blaese RM, Brenner MK, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther 1997; 8(18): 2301–38PubMedCrossRef
21.
Murphy G, Tjoa B, Ragde R, et al. Phase 1 clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A020 1-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29(6): 371–80PubMedCrossRef
22.
Chakraborty NG, Sporn JR, Tortora AR, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Im-munother 1998; 47(1): 58–64CrossRef
23.
Hsti FJ, Benike C, Fagoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–8CrossRef
24.
Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997 Jul 22; 94(15): 8099–103PubMedCrossRef
25.
Daniel PT, Kroidal A, Cayeux S, et al. Costimulatory signals through 137. 1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997; 159: 3808–15PubMed
26.
Parney IE, Petruk KC, Zliang C, et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 1997; 8(9): 1073–85PubMedCrossRef
27.
28.
Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9(4): 532–62PubMed
29.
Pellegrini R, Berghella AM, Del Beato T, et al. Dysregulation in THI and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42(1): 1–8PubMedCrossRef
30.
Sato M, Goto S, Kaneko R, et al. Impaired production of Thl cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 1998; 18(5D): 3951–5PubMed
31.
Lowes MA, Bishop GA, Crotty K, et al. T helper 1 cytokine mRNAis increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108(6): 914–9PubMedCrossRef
32.
Wagner SN, Schultewolter T, Wagner C, et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998; 78(5): 541–50PubMed
33.
Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998; 161(6): 3033–4lPubMed
34.
Inagawa H, Nishizawa T, Honda T, et al. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th.2 to Thl in tumor lesions. Anticancer Res 1998; 18(5D): 3957–64PubMed
35.
Hrouda D, Baban B, Dunsmuir WD, et al. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL 172). Br J Urol 1998; 82(4): 568–73PubMedCrossRef
36.
Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46(10): 5276–81PubMed
37.
Freeman SM, Abboud CN, Whartertby KA, et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53(21): 5274–83PubMed
38.
Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exp Hematol 1996; 24(7): 829–38PubMed
39.
Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the I-ISVtk gene involves an immune component. Cancer Res 1994; 54(23): 6228–34PubMed
40.
Ramesh R, Munshi A, Marrogi AJ, et al. Enhancement of tumor killing using a combination of tumor immunization and HW-tk suicide gene therapy. Int J Cancer 1999; 80(3): 380–6PubMedCrossRef
41.
Klanmanesh AR, Perrin H, Panis Y, et al. A ‘distant’ bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997; 8(15): 1807–14CrossRef
42.
Moller R, Sun Y, Dorbic T, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998; 77(11): 1907–16PubMedCrossRef
43.
Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase 1 study. Gene Ther 1998; 5(4): 481–90PubMedCrossRef
44.
Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated turnor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A 1993 Apr 15; 90(8): 3539–43PubMedCrossRef
45.
Dranoff G, Soiffer R, Lynch T, et al. Aphase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997; 8(1): 111–23PubMedCrossRef
46.
Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998 Oct 27; 95(22): 13141–6PubMedCrossRef
47.
Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997: 57(8): 1537–46PubMed
48.
Mackensen A, Veelken H, Lahn M, et al. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med 1997: 75(4): 290–6PubMedCrossRef
49.
Veelken H, Mackensen A, Lahn M, et al. A phase-1 clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 1997; 70(3): 269–77PubMedCrossRef
50.
Vieweg J, Rosenthal FM, Bannedi R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene-modified tumor vaccines. Cancer Res 1994; 54(7): 1760–5PubMed
51.
Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151(3): 622–8PubMed
52.
Peelil DM, Starney TA. Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. Prostate 1986; 8(1): 51–61CrossRef
53.
Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting M1IC class 1-restricted tumor antigens. Science 1994; 264(5161): 961–5PubMedCrossRef
54.
Knight BC, Souberbielle BE, Rizzardi GP, et al. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6(4): 299–306PubMedCrossRef
55.
Souberbielle BE, Westby M, Gariz S, et al. Comparison of four strategies for tumour vaccination in the B 16-F10 melanoma model. Gene Ther 1998; 5(11): 1447–54PubMedCrossRef
56.
Ashley DM, Falola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186(7): 1177–82PubMedCrossRef
57.
Lim YS, Kang BY, Kim EJ, et al. Augmentation of therapeutic antiturnor immunity by B 16F10 melanoma cells transfected by interferon-gamma and allogeneic MHC class 1 cDNAs. Mol Cells 1998; 8(5): 629–36PubMed
58.
Thomas MC, Greten TF, Pardoll DM, et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998; 9(6): 835–43PubMedCrossRef
59.
Hrouda D, Souberbielle BE, Kayaga J, et al. Mycobacterium vaccae (SRL 172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 1998; 82(6): 870–6PubMedCrossRef
Metadata
Title
Prospects for Vaccination in Prostate Cancer
Authors
Matthew J. A. Perry
David Hrouda
Angus G. Dalgleish
Publication date
01-05-2000
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 5/2000
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200016050-00001

Other articles of this Issue 5/2000

Drugs & Aging 5/2000 Go to the issue

Review Article

Heparin-Induced Thrombocytopenia

Review Article

Proper Use of Antiarrhythmic Therapy for Reduction of Mortality After Myocardial Infarction

Review Article

Silent Myocardial Ischaemia in the Elderly

Disease Management

Chronic Vaginal Candidiasis

Review Article

Role of Dopamine in Learning and Memory

Leading Article

Colon Cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits